Mantle Cell Lymphoma — Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
Citation(s)
A Trial of Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in CD20+, B-cell Lymphomas, Gray Zone Lymphoma, and Hodgkin's Lymphoma